

COMMENTARY

Open Access



It's TIME for a biomarker-driven approach to cancer immunotherapy

Leisha A. Emens

Cancer immunotherapy has clearly taken its place in the clinic as one pillar of cancer care. Immune checkpoint blockade, which unleashes the activity of pre-existing T cells at the tumor site, is transforming cancer treatment. The FDA approval of the cytotoxic T lymphocyte antigen-4 (CTLA-4) antagonist ipilimumab for unresectable or metastatic melanoma on March 25, 2011 forged a path for the further clinical development of immune checkpoint modulation. Building on its success, antagonists of the programmed death-1 (PD-1) pathway have now been approved for use in advanced melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, bladder cancer, and Hodgkin's disease. Blockade of the PD-1 pathway produces durable objective responses in 20–30 % of patients with solid tumors, with clear activity in multiple other cancer types as well [1]. This striking clinical success has re-invigorated interest in cancer immunotherapy, promoted the rapid growth of the immuno-oncology pipeline, and accelerated the clinical development of treatment strategies that engage the immune system to treat cancer.

Therapeutic cancer vaccines, designed to promote the activation and expansion of T cells, have been studied in the clinic since the late 1800's with mostly negative results. This lack of success has been attributed to both suboptimal vaccine formulations, flawed clinical development plans, and dominant mechanisms of immune tolerance and suppression in the tumor microenvironment that prevent T cell activity [2–4]. There was a flash of hope for therapeutic cancer vaccines on April 29, 2010 when the FDA approved sipuleucel-T for the treatment of asymptomatic or minimally symptomatic castrate-resistant prostate cancer. Sipuleucel-T is a cellular immunotherapy product composed of autologous peripheral blood mononuclear cells (PBMC) obtained by leukapheresis and activated with a recombinant fusion protein that delivers the tumor antigen prostatic

acid phosphatase (PAP) linked to the immune-activating cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). The pivotal trial was a placebo-controlled multicenter trial that randomized 512 patients at a 2:1 ratio to receive three infusions of sipuleucel-T or unactivated control PBMC over the course of 1 month. It demonstrated a modest 4.1-month improvement in overall survival, where the sipuleucel-T-treated and control groups had a median overall survival of 25.8 and 21.7 months, respectively (HR = 0.775, 95 % CI 0.61–0.098, $p = 0.032$) [5]. There was no impact on progression free survival. Unfortunately, the complexity of the manufacturing process, the cost, and the rapidly changing landscape of prostate cancer therapy led to slow uptake of sipuleucel-T and the original manufacturer ultimately declared bankruptcy.

Despite these challenges, interest in cancer vaccines is growing. Quiox and colleagues recently reported promising results of the Phase 2b portion of the TIME trial, a Phase 2b/3 clinical trial testing the vaccine TG4010 combined with chemotherapy in patients with advanced NSCLC [6]. TG4010 is a recombinant modified vaccinia Ankara virus that delivers the tumor antigen mucin-1 (MUC-1) with the immune-activating cytokine interleukin-2 (IL-2). The induction of an immune response specific for MUC-1 is enhanced both by danger signals present in the viral vector and by local expression of IL-2 at the vaccine site. The Phase 2b/3 trial was based on promising results of earlier randomized trials demonstrating the safety and clinical activity of TG4010 in combination with chemotherapy in NSCLC [7, 8]. These trials identified a candidate predictive biomarker: TrPAL, activated natural killer cells triple positive for CD16, CD56, and CD69. A low baseline level of TrPAL appeared to predict for TG4010 activity in combination with chemotherapy; the 25 % of patients with the highest TrPAL values did not benefit, whereas the 75 % of patients with the lowest TrPAL levels did. High levels of TrPAL are thought to suppress the induction of an adaptive immune response by TG4010. This apparent conundrum may be explained by the dual role of natural killer cells in the regulation of adaptive immunity.

Correspondence: emense@jhmi.edu

Department of Oncology, Johns Hopkins University School of Medicine, The Kimmel Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building 1, 1650 Orleans Street, Room 409, Baltimore, MD 21231-1000, USA



© 2016 The Author(s). **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

The TIME trial is a randomized, double-blind, placebo-controlled Phase 2b/3 trial that enrolls previously untreated patients with stage 4 NSCLC without a known activating *EGFR* mutation and with MUC-1 expression in at least 50 % of tumor cells [6]. In the Phase 2b portion, 222 patients were randomized 1:1 to receive 10^8 plaque-forming units (pfu) of TG4010 or placebo (the formulation buffer of TG4010) from the initiation of chemotherapy weekly for 6 weeks, and then every 3 weeks until disease progression. Randomized patients were stratified according to the baseline level of TrPAL (\leq or $>$ the upper limit of normal (ULN)). Chemotherapy was a platin-based doublet given at standard doses for up to 6 cycles, and bevacizumab and maintenance treatment with pemetrexed or erlotinib were permitted as clinically indicated. The primary endpoint was PFS assessed every 6 weeks to validate the predictive value of the TrPAL biomarker. For the population as a whole, the median PFS for the TG4010 and placebo groups was 5.9 months (95 % CI 5.4–6.7) and 5.1 months (95 % CI 4.2–5.9) respectively (HR = 0.74, 95 % CI 0.55–0.98, one-sided $p = 0.019$). The treatment effect of adding TG4010 to chemotherapy was delayed, consistent with reported data with other cancer immunotherapies like sipuleucel-T and ipilimumab [5, 9]. The study validated the association of the TrPAL biomarker with benefit in patients with a TrPAL value \leq ULN, but not the association of the TrPAL biomarker with lack of benefit in patients with a TrPAL value $>$ ULN. As this threshold corresponded to the first 3 quartiles (Q3) of the patient distribution (75 %) in the earlier Phase 2b trial [7], a pre-specified analysis demonstrated the patients with TrPAL values \leq Q3 had a significant improvement in PFS, but those with TrPAL values $>$ Q3 did not. Based on these data supporting an improvement in PFS with TG4010 with chemotherapy relative to control, and the predictive value of a low baseline level of TrPAL, the study continues to fully evaluate the clinical activity of TG4010 and to validate TrPAL as a companion predictive biomarker in this patient population.

Importantly, the TIME trial evaluated multiple biomarkers. First, it required expression of the tumor antigen MUC-1 in at least 50 % of tumor cells for eligibility. This is important as MUC-1 is the target of the vaccine-induced T cell response. Ensuring adequate levels of expression of the target antigen by the tumor is thus critical for success. Although not reported here, an association between the clinical activity of TG4010 and MUC-1-specific T cells in NSCLC patients has been reported in an earlier trial (8). Second, it evaluated the TrPAL biomarker as an additional predictive biomarker of benefit with the combination of TG4010 and chemotherapy. The investigators demonstrated that low levels of TrPAL appear to predict clinical benefit from TG4010

combined with chemotherapy. Third, in a post-hoc exploratory analysis, the investigators evaluated expression of PD-L1 in available pretreatment tumor specimens; 160 (72 %) patients were assessable for tumor cell PD-L1 expression, and 137 (62 %) patients were assessable for PD-L1 expression in infiltrating immune cells. They noted a significant improvement in PFS with TG4010 and chemotherapy relative to the control group in patients with a low level of PD-L1 expression in the immune cell infiltrate, but not in those with higher levels of PD-L1 expression in the immune cell infiltrate (HR 0.61 [95 % CI 0.39–0.96]; $p = 0.015$). The level of PD-L1 expression by tumor cells appeared to make no difference. This finding raises the interesting possibility that adding a PD-1 or PD-L1 antagonist to block intratumoral immune suppression in patients with higher levels of PD-L1 expression at the tumor site could expand the number of patients who respond to TG4010 combined with chemotherapy. Prospective clinical trials will be required to test these hypotheses.

Where are we with simple predictive biomarkers in cancer immunotherapy? The PD-1 antagonist pembrolizumab was granted accelerated approval by the FDA on October 2, 2015 for the second line treatment of advanced PD-L1+ NSCLC together with the companion diagnostic PD-L1 IHC22C3 pharmDx test. This approval was based on objective response rates of 45 % in PD-L1+ patients relative to 19 % in all patients enrolled on the trial [10]. Nivolumab and atezolizumab also appear to have greater activity in tumors that express PD-L1 [11–15], and nivolumab is also FDA-approved for the second line therapy of NSCLC. Separately, a diagnostic test for PD-L1 expression, the PD-L1 IHC 28-8 Pharm Dx test, was approved to help physicians select patients more likely to benefit from PD-1 blockade with nivolumab. Thus, PD-L1 expression within the tumor microenvironment appears to enrich for responders to antagonists of the PD-1 pathway, but is an imperfect biomarker due in part to geographic variability in expression within a given tumor and across tumor metastases, and dynamic changes in PD-L1 expression over time. Microsatellite instability (MSI) has more recently been proposed as a predictive biomarker of response to pembrolizumab based on response rates of 40 and 0 % in mismatch repair deficient and proficient tumors, respectively [16]. This is thought to reflect a higher load of neoantigens generated by mutation in the mismatch repair deficient tumors, rendering them more immunogenic. These findings are being further explored and validated in larger trials. With these advances, we are beginning to develop informative predictive biomarkers of response to cancer immunotherapies. An association between the baseline level of TrPAL and the response of MUC-1+ NSCLC to TG4010 and chemotherapy, if validated in the Phase 3 portion of the TIME trial, could

add another promising predictive biomarker to our toolbox. Companion predictive biomarkers of response and resistance to cancer immunotherapies are important to identify the patients most likely to respond, thus avoiding unnecessary toxicity and cost in patients unlikely to benefit. Thus, elucidating reliable biomarkers of response and resistance to established and emerging cancer immunotherapies should continue to be a high priority for clinical development.

Financial disclosures

This work was supported in part by the Breast Cancer Research Foundation and the Allegheny Health Network/Johns Hopkins Partnership.

Competing interests

Dr. Emens receives research funding or material support from Genentech/Roche, Merck, EMD Serono, Maxcyte, Astrazeneca, Aduro Biotech, and Corvus Pharmaceuticals. She has served on advisory boards for and received honoraria from Astrazeneca, Amgen, Bristol Meyers Squibb, Celgene, Roche, Syndax, and Vaccinex. Under a licensing agreement between Aduro Biotech and The Johns Hopkins University, the University and Dr. Emens are entitled to milestone payments and royalty on sales of a licensed vaccine product. The terms of these arrangements are being managed by The Johns Hopkins University in accordance with its conflict of interest policies.

Received: 7 April 2016 Accepted: 8 July 2016

Published online: 16 August 2016

References

- Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. *Semin Oncol*. 2015; 42:587–600.
- Emens LA, Jaffee EM. Cancer vaccines: on the threshold of success. *Cancer Biol Ther*. 2003;2(Suppl1):S161–8.
- Emens LA. Roadmap to a better therapeutic tumor vaccine. *Intl Rev Immunol*. 2006;25:415–43.
- Emens LA, Silversten SC, Khleif S, Marincola FM, Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. *J Transl Med*. 2012;10:70. doi:10.1186/1479-5876-10-70.
- Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Pensen DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*. 2010;363:411–22.
- Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. *Lancet Oncol*. 2016; 17:212–23.
- Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2b trial. *Lancet Oncol*. 2011;12:1125–33.
- Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, et al. A phase II study of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with stage III/IV non-small-cell lung cancer. *J Thorac Oncol*. 2008;3:735–44.
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;19:711–23.
- Garon EB, Rizvi NA, Hui R, Leigh N, Balmonoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015;372:2018–28.
- Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*. 2015;373:123–35.
- Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*. 2015;373:1627–39.
- Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature*. 2014;515:563–7.
- Powles T, Eder JP, Fine GD, Braiteh FS, Lortot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature*. 2014;555:558–62.
- Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet*. 2016;387:1909–20.
- Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med*. 2015; 372:2509–20.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

